da Silva Marcela Cunha, Fidalski Solena Ziemer Kusma, Boguszewski Cesar Luiz
SEMPR (Endocrine Division), Department of Internal Medicine, Federal University of Parana, Agostinho Leão Junior 285, Curitiba, 80030-110, PR, Brazil.
Department of Community Health, Federal University of Parana, Curitiba, Brazil.
Pituitary. 2024 Dec;27(6):992-999. doi: 10.1007/s11102-024-01456-2. Epub 2024 Sep 9.
To evaluate the prevalence and characteristics of SARS-CoV-2 infection, and the prevalence, efficacy, and safety of anti-SARS-CoV-2 vaccination in patients with pituitary diseases.
Observational, cross-sectional study of adult patients with pituitary diseases followed in a reference center. Clinical data were collected and a questionnaire about SARS-CoV-2 infection, vaccination and its possible adverse effects was applied. COVID-19 disease severity was defined as mild, moderate, and severe according to the WHO classification.
145 patients were studied (79 women; age 50 ± 15.8 years; duration of pituitary disease 16.8 ± 11.5 years), the cause of pituitary disease was tumoral in 74.5%, and 45.9% were on glucocorticoid replacement due to ACTH deficiency. SARS-CoV-2 infection was confirmed in 51 patients (35.2%; 32 women; age 53.8 ± 14.8 years, 22 before vaccination), with 28 (54.9%), 17 (33.3%) and 6 (11.8%) cases of mild, moderate, and severe disease, respectively, and hospitalization was indicated in 7 (14%) cases. One mild case presented pituitary apoplexy after SARS-CoV-2 infection. Advanced age was a risk factor for COVID-19. Patients with moderate and severe forms of COVID-19 had higher prevalence of dyslipidemia and duration of pituitary disease. All but one of the participants were vaccinated against COVID-19, and 60.4% had adverse events, the most common local pain (54.0%), fever (33.3%), and headache (18.4%), with one case of alopecia and two of persistent fatigue.
The prevalence of SARS-CoV-2 infection in our cohort was 35.2%, including 14% of moderate and severe cases requiring hospitalization. The vaccination was universal and safe.
评估垂体疾病患者中新型冠状病毒2（SARS-CoV-2）感染的患病率及特征，以及抗SARS-CoV-2疫苗接种的患病率、疗效和安全性。
在一家参考中心对成年垂体疾病患者进行观察性横断面研究。收集临床数据，并应用一份关于SARS-CoV-2感染、疫苗接种及其可能不良反应的问卷。根据世界卫生组织分类，将新型冠状病毒肺炎（COVID-19）疾病严重程度定义为轻度、中度和重度。
共研究了145例患者（79例女性；年龄50±15.8岁；垂体疾病病程16.8±11.5年），垂体疾病的病因在74.5%为肿瘤性，45.9%因促肾上腺皮质激素（ACTH）缺乏接受糖皮质激素替代治疗。51例患者（35.2%；32例女性；年龄53.8±14.8岁，22例在接种疫苗前）确诊感染SARS-CoV-2，其中轻度、中度和重度病例分别为28例（54.9%）、17例（33.3%）和6例（11.8%），7例（14%）需要住院治疗。1例轻度病例在感染SARS-CoV-2后出现垂体卒中。高龄是COVID-19的危险因素。中度和重度COVID-19患者血脂异常患病率更高，垂体疾病病程更长。除1名参与者外，其他所有参与者均接种了COVID-19疫苗，60.4%出现不良事件，最常见的是局部疼痛（54.0%）、发热（33.3%）和头痛（18.4%），1例脱发和2例持续性疲劳。
我们队列中SARS-CoV-2感染的患病率为35.2%，包括14%需要住院治疗的中度和重度病例。疫苗接种率高且安全。
